Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:16 2024-04-16 am EDT			5-day change	1st Jan Change
13.23 ^EUR	-3.99%		-8.06%	-37.83%

Apr. 12	Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome	DP
Apr. 12	STOXX 600 climbs over 1% on rate-cut optimism	RE

Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

August 30, 2019 at 07:30 am EDT

DGAP Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement
Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

30.08.2019 / 13:24
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
X	Conditional capital increase (Sec. 41 para. 2 WpHG)	30.08.2019
	Other capital measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:

150123640

30.08.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Evotec SE
	Manfred Eigen Campus / Essener Bogen 7
	22419 Hamburg
	Germany
Internet:	www.evotec.com


End of News	DGAP News Service

866295 30.08.2019

Latest news about Evotec SE

Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome	Apr. 12	DP
STOXX 600 climbs over 1% on rate-cut optimism	Apr. 12	RE
Deutsche Bank Research raises Evotec to 'Buy' - Target 19 Euro	Apr. 12	DP
EVOTEC : Deutsche Bank takes a positive view	Apr. 12	ZD
U.S. Futures, European Stocks Up as ECB Signals Moving Closer to Rate Cut	Apr. 12	DJ
EVOTEC : Receives a Buy rating from Jefferies	Mar. 28	ZD
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Sofinnova Investment, Inc., Evotec SE, venBio LLC, Apollo Health Ventures, b2venture AG, Hevolution Foundation	Mar. 27	CI
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG	Mar. 27	CI
Tubulis Technologies announced that it has received ?128 million in funding from a group of investors	Mar. 13	CI
Evotec Grants Claris Ventures Portfolio Biotech Firms Access to Testing Platform	Mar. 06	MT
EVOTEC : Warburg Research maintains a Buy rating	Mar. 05	ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading	Feb. 07	MT
Evotec Unit, Advanced BioScience Expand Agreement to Develop Antibodies Against HIV	Feb. 07	MT
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories	Feb. 07	MT
EVOTEC : RBC remains its Buy rating	Jan. 26	ZD
Jefferies lowers target for Evotec to 28 Euro - 'Buy'	Jan. 26	DP
EVOTEC : Jefferies remains its Buy rating	Jan. 26	ZD
Global markets live: Crest Nicholson, Gilead, United Airlines, 3M Company, General Electric...	Jan. 23
EVOTEC : RBC gives a Buy rating	Jan. 23	ZD
Evotec Says Former CEO Failed to Disclose Stock Trades Over 3 Years	Jan. 22	MT
Evotec Reiterates Trading Regulations Compliance Amid Former CEO’s Late Stock Trades Disclosure	Jan. 22	MT
Evotec says it promptly reported share trades withheld by former CEO	Jan. 22	RE
Transcript : Evotec SE - Special Call	Jan. 22
Evotec share price decline halted for the time being - upgrade helps	Jan. 18	DP
RBC raises Evotec to 'Outperform' - Target 18.60 Euro	Jan. 18	DP

Chart Evotec SE

Duration

Period

More charts

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - Q4 2023 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.78 EUR

Average target price

25.4 EUR

Spread / Average Target

+84.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-37.83%	2.6B
LONZA GROUP AG	+48.77%	42.16B
IQVIA HOLDINGS INC.	-0.97%	42.07B
MODERNA, INC.	+4.36%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+3.87%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-23.35%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.72%	12.11B
MEDPACE HOLDINGS, INC.	+25.62%	11.99B
UNITED THERAPEUTICS CORPORATION	+5.32%	11.06B

Other Biotechnology & Medical Research